Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting

Concurrent chemoradiotherapy (CRT) followed by maintenance treatment with the PD-L1 inhibitor durvalumab is a new standard of care for inoperable stage III NSCLC. The present study compares the oncological outcome of patients treated with CRT to those treated with CRT and durvalumab (CRT-IO) in the...

Full description

Bibliographic Details
Main Authors: Julian Taugner, Lukas Käsmann, Chukwuka Eze, Amanda Tufman, Niels Reinmuth, Thomas Duell, Claus Belka, Farkhad Manapov
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
NSCLC
multimodal treatment
stage III
real world data
durvalumab
Online Access:https://www.mdpi.com/2072-6694/13/7/1613

Internet

https://www.mdpi.com/2072-6694/13/7/1613

Similar Items